MX9802809A - Urease for the treatment of helicobacter pylori infections. - Google Patents

Urease for the treatment of helicobacter pylori infections.

Info

Publication number
MX9802809A
MX9802809A MX9802809A MX9802809A MX9802809A MX 9802809 A MX9802809 A MX 9802809A MX 9802809 A MX9802809 A MX 9802809A MX 9802809 A MX9802809 A MX 9802809A MX 9802809 A MX9802809 A MX 9802809A
Authority
MX
Mexico
Prior art keywords
treatment
urease
helicobacter pylori
pylori infections
infections
Prior art date
Application number
MX9802809A
Other languages
Spanish (es)
Inventor
Bow Ho
Original Assignee
Cortecs Internat Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9520585.2A external-priority patent/GB9520585D0/en
Application filed by Cortecs Internat Ltd filed Critical Cortecs Internat Ltd
Publication of MX9802809A publication Critical patent/MX9802809A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides novel therapies for the treatment of H. pylori infections, as well as pharmaceutical formulations for use in such methods.
MX9802809A 1995-10-09 1998-04-08 Urease for the treatment of helicobacter pylori infections. MX9802809A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9520585.2A GB9520585D0 (en) 1995-10-09 1995-10-09 Therapeutic method
US1588296P 1996-04-19 1996-04-19

Publications (1)

Publication Number Publication Date
MX9802809A true MX9802809A (en) 1998-11-29

Family

ID=26307915

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9802809A MX9802809A (en) 1995-10-09 1998-04-08 Urease for the treatment of helicobacter pylori infections.

Country Status (9)

Country Link
EP (1) EP0862458A1 (en)
JP (1) JPH11514998A (en)
KR (1) KR19990064104A (en)
CN (1) CN1201395A (en)
AU (1) AU7141096A (en)
BR (1) BR9611033A (en)
MX (1) MX9802809A (en)
NO (1) NO981594L (en)
WO (1) WO1997013527A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103667127A (en) * 2006-11-14 2014-03-26 根特大学 Culture of Helicobacter in vitro
US7939079B2 (en) 2006-11-14 2011-05-10 Universiteit Gent Helicobacter species and cultivation thereof
JP5145700B2 (en) * 2006-11-20 2013-02-20 学校法人慶應義塾 Career

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection

Also Published As

Publication number Publication date
AU7141096A (en) 1997-04-30
EP0862458A1 (en) 1998-09-09
JPH11514998A (en) 1999-12-21
NO981594L (en) 1998-06-03
KR19990064104A (en) 1999-07-26
CN1201395A (en) 1998-12-09
WO1997013527A1 (en) 1997-04-17
NO981594D0 (en) 1998-04-07
BR9611033A (en) 1999-12-28

Similar Documents

Publication Publication Date Title
MX9704030A (en) 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof.
AP9801392A0 (en) Concentrated antibody preparation.
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
ZA965752B (en) Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents.
ATE223413T1 (en) NEW CONNECTIONS
NZ333380A (en) 6-O-methylerythromycin A crystal form I (clarithromycin) and preparation thereof
DE69808765D1 (en) LINKS
MX9709238A (en) Pharmaceutical and diet formulations for the prophylaxis and treatment of gastrointestinal disorders.
IL127918A0 (en) Novel amino sugar and related sugar derivatives of indolylopyrrolocarbazoles their use as antitumor agents and pharmaceutical formulations
UA48940C2 (en) Il4 mabs used for treatment of il4-mediated diseases
EP0793660A4 (en) 2-substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof
EP0831892A4 (en) Multimeric, recombinant urease vaccine
DE69911401D1 (en) Immunoregulator
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
ZA943553B (en) Tri(platinum) complexes
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
AU6580494A (en) Use of clioquinol for treating helicobacter, including (h. pylori), infections and related diseases
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
MX9802809A (en) Urease for the treatment of helicobacter pylori infections.
PL318262A1 (en) Imidazopyridine azolydinones
AP2001002369A0 (en) Pharmaceutical complex.
UA42741C2 (en) Peptide of mastitis vaccine (variants), the peptide of complex antigenic idea (variants), pharmaceutical composition (variants)
NZ505085A (en) Pharmaceutical compositions comprising bipapcitide monocarboxylate and/or bipapcitide dicarboxylate for imaging and treating thrombi
GB9615710D0 (en) Pharmaceutical preparations for the treatment of sarcocystosis
AP9600780A0 (en) Process for the preparation of peroxetine hydrochloride anhydrate and its use as therapeutic agent.